PATENT CLAIM ANALYSIS

Application Number: 16144198
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-03
Patent Classification: ["514", "263100"]

Abstract:
The disclosure provides methods for treating cancer, including but not limited to, hematopoietic and lung cancers, using the HSP90 inhibitor, MPC-0767, as monotherapy and in combination therapy with additional active agents, including but not limited to, inhibitors of Bcl-2, EZH2 inhibitors, Ras/Raf/MEK/ERK pathway inhibitors, checkpoint inhibitors, DNMT inhibitors, ATO and chemotherapeutic agents. The disclosure also provides related compositions and methods of use.

Claim (Index 59):
The method of  claim 58 , wherein the FLT3 inhibitor is selected from crenolanib, gilteritinib, midostaurin, quizartinib, and sorafenib.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 97.0
- Lexical Diversity: 1.65217
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15419642', '15514043', '14671613', '14026778', '14447139']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7988183559800214
- 35 USC 102 Novelty (BERT): 0.5234157073385391
- Combined Prediction Score: 0.7712780911158732
- Mean Citation Score: 313.314552
- Max Citation Score: 320.49805
- Similarity Product: 215.0295496801793

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test